Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety and Immunogenicity of CMAB809 vs Trastuzumab in Healthy Men
NCT04049409Phase 1Completed
- Sponsor
- Taizhou Mabtech Pharmaceutical
- Start
- Jun 2019
- Primary completion
- Nov 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cmab809 in HER2-positive breast cancer and gastric cancer (GC) (2 arms), sponsored by Taizhou Mabtech Pharmaceutical. Primary endpoint: Area under the concentration-time curve at 1680 hours. Started Jun 2019; status: completed.
02
Drugs
cmab809
03
Conditions
HER2-positive breast cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT04049409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04049409.